A chemogenomic analysis of the transmembrane binding cavity of human G-protein-coupled receptors

Proteins: Structure, Function and Genetics

Volumn 62, Issue 2, 2006, Pages 509-538

  Surgand, Jean Sebastien ^a   Rodrigo, Jordi ^a   Kellenberger, Esther ^a   Rognan, Didier ^a  

^a CNRS   (France)

Author keywords

Amino acid sequences; Bovine rhodopsin; Human G protein coupled receptors; Transmembrane domain

Indexed keywords

ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; AMINO ACID; CANNABINOID 2 RECEPTOR; CHEMOKINE RECEPTOR; CHOLECYSTOKININ RECEPTOR; DOPAMINE RECEPTOR; FRIZZLED PROTEIN; G PROTEIN COUPLED RECEPTOR; GLUTAMATE RECEPTOR; GLYCOPROTEIN; GONADORELIN RECEPTOR; HISTAMINE RECEPTOR; LYSOPHOSPHATIDIC ACID RECEPTOR; MELATONIN RECEPTOR; NEUROKININ 1 RECEPTOR; NEUROKININ 2 RECEPTOR; NEUROPEPTIDE Y RECEPTOR; OPIATE RECEPTOR; OXYTOCIN RECEPTOR; PROSTANOID RECEPTOR; PURINE RECEPTOR; RECEPTOR SUBTYPE; RHODOPSIN; SECRETIN; SEROTONIN RECEPTOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR; VASCULOTROPIN RECEPTOR;

AMINO ACID SEQUENCE; ARTICLE; BINDING SITE; CATTLE; GENOMICS; HUMAN; MEMBRANE BINDING; MOLECULAR MODEL; NONHUMAN; PHYLOGENETIC TREE; PRIORITY JOURNAL; PROTO ONCOGENE; THREE DIMENSIONAL IMAGING;

AMINO ACID SEQUENCE; BINDING SITES; GENOMICS; HUMANS; LIGANDS; MODELS, MOLECULAR; PHYLOGENY; RECEPTORS, G-PROTEIN-COUPLED;

BOS TAURUS; BOVINAE;

EID: 30144441512     PISSN: 08873585     EISSN: None     Source Type: Journal    
DOI: 10.1002/prot.20768     Document Type: Article

References (198)

1. Horn F, Bettler E, Oliveira L, Campagne F, Cohen FE, Vriend G. GPCRDB information system for G protein-coupled receptors. Nucleic Acids Res 2003;31:294-297.
2. Kristiansen K. Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function. Pharmacol Ther 2004;103:21-80.
3. Klabunde T, Hessler G. Drug design strategies for targeting G-protein-coupled receptors. Chembiochem 2002;3:928-944.
4. Gether U. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr Rev 2000;21:90-113.
5. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, et al. Initial sequencing and analysis of the human genome. Nature 2001;409:860-921.
6. Wise A, Jupe SC, Rees S. The identification of ligands at orphan G-protein coupled receptors. Annu Rev Pharmacol Toxicol 2004;44: 43-66.
7. Kolakowski Jr. LF. GCRDb: a G-protein-coupled receptor data-base. Recept Channels 1994;2:1-7.
8. Attwood TK, Findlay JB. Fingerprinting G-protein-coupled receptors. Protein Eng 1994;7:195-203.
9. Krogh A, Larsson B, von Heijne G, Sonnhammer EL. Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes. J Mol Biol 2001;305:567-580.
10. Joost P, Methner A. Phylogenetic analysis of 277 human G-protein-coupled receptors as a tool for the prediction of orphan receptor ligands. Genome Biol 2002;3:RESEARCH0063.
11. Karchin R, Karplus K, Haussler D. Classifying G-protein coupled receptors with support vector machines. Bioinformatics 2002;18: 147-159.
12. Qian B, Soyer OS, Neubig RR, Goldstein RA. Depicting a protein's two faces: GPCR classification by phylogenetic tree-based HMMs. FEBS Lett 2003;554:95-99.
13. Attwood TK. A compendium of specific motifs for diagnosing GPCR subtypes. Trends Pharmacol Sci 2001;22:162-165.
14. Elrod DW, Chou KC. A study on the correlation of G-protein-coupled receptor types with amino acid composition. Protein Eng 2002;15:713-715.
15. Lapinsh M, Gutcaits A, Prusis P, Post C, Lundstedt T, Wikberg JE. Classification of G-protein coupled receptors by alignment-independent extraction of principal chemical properties of primary amino acid sequences. Protein Sci 2002;11:795-805.
16. Fredriksson R, Lagerstrom MC, Lundin LG, Schioth HB. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and finger-prints. Mol Pharmacol 2003;63:1256-1272.
17. Strader CD, Sigal IS, Dixon RA. Genetic approaches to the determination of structure-function relationships of G protein-coupled receptors. Trends Pharmacol Sci 1989;Suppl:26-30.
18. Trumpp-Kallmeyer S, Hoflack J, Bruinvels A, Hibert M. Modeling of G-protein-coupled receptors: application to dopamine, adrenaline, serotonin, acetylcholine, and mammalian opsin receptors. J Med Chem 1992;35:3448-3462.
19. Jacoby E. A novel chemogenomics knowledge-based ligand design strategy - application to G Protein coupled receptors. Quant Struct-Act Relat 2001;20:115-123.
20. Bywater RP. Location and nature of the residues important for ligand recognition in G-protein coupled receptors. J Mol Recognit 2005;18:60-72.
21. Jacoby E, Schuffenhauer A, Acklin P. In: Kubinyi H, Müller G, editors. Chemogenomics in drug discovery - a medicinal chemistry perspective. Weinheim: Wiley-VCH; 2004. p 139-166.
22. Crossley R. The design of screening libraries targeted at G-protein coupled receptors. Curr Top Med Chem 2004;4:581-588.
23. Apweiler R, Bairoch A, Wu CH, Barker WC, Boeckmann B, Ferro S, Gasteiger E, et al. UniProt: the Universal Protein knowledge-base. Nucleic Acids Res 2004;32:D115-119.
24. Wheeler DL, Church DM, Edgar R, Federhen S, Helmberg W, Madden TL, Pontius JU, et al. Database resources of the National Center for Biotechnology Information: update. Nucleic Acids Res 2004;32:D35-40.
25. Bissantz C, Logean A, Rognan D. High-throughput modelling of human G-Protein coupled receptors: amino acid sequence alignment, three-dimensional model building, and receptor library screening. J Chem Info Comput Sci 2004;44:1162-1176.
26. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Trong IL, et al. Crystal structure of rhodopsin: A G protein-coupled receptor. Science 2000;289:739-745.
27. Sneath PH, Sokal RR. Numerical taxonomy. Nature 1962;193:855-860.
28. Perriere G, Gouy M. WWW-query: an on-line retrieval system for biological sequence banks. Biochimie 1996;78:364-369.
29. Exner TE, Keil M, Moeckel G, Brickmann J. Identification of substrate channels and protein cavities. J Mol Model 1998;98:440-443.
30. SYBYL. 6.91., TRIPOS, Assoc., Inc., St-Louis, MO.
31. Bondensgaard K, Ankersen M, Thogersen H, Hansen BS, Wulff BS, Bywater RP. Recognition of privileged structures by G-protein coupled receptors. J Med Chem 2004;47:888-899.
32. Ballesteros JA, Shi L, Javitch JA. Structural mimicry in G protein-coupled receptors: implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors. Mol Pharmacol 2001;60:1-19.
33. Miller JR. The Wnts. Genome Biol 2002;3:REVIEWS3001.
34. Williams JA, Guicherit OM, Zaharian BI, Xu Y, Chai L, Wichterle H, Kon C, et al. Identification of a small molecule inhibitor of the hedgehog signaling pathway: effects on basal cell carcinoma-like lesions. Proc Natl Acad Sci USA 2003;100:4616-4621.
35. Chen JK, Taipale J, Young KE, Maiti T, Beachy PA. Small molecule modulation of Smoothened activity. Proc Natl Acad Sci USA 2002;99:14071-14076.
36. Harmar AJ. Family-B G-protein-coupled receptors. Genome Biol 2001;2:REVIEWS3013.
37. Grace CR, Perrin MH, DiGruccio MR, Miller CL, Rivier JE, Vale WW, Riek R. NMR structure and peptide hormone binding site of the first extracellular domain of a type B1 G protein-coupled receptor. Proc Natl Acad Sci USA 2004;101:12836-12841.
38. Collins JL, Dambek PJ, Goldstein SW, Faraci, W. Stephen. CP-99,711: a non-peptide glucagon receptor antagonist. Bioorg Med Chem Lett 1992;2:915-918.
39. Cascieri MA, Koch GE, Ber E, Sadowski SJ, Louizides D, de Laszlo SE, Hacker C, et al. Characterization of a novel, non-peptidyl antagonist of the human glucagon receptor. J Biol Chem 1999;274: 8694-8697.
40. Kurukulasuriya R, Sorensen BK, Link JT, Patel JR, Jae H-S, Winn MX, Rohde JR, Grihalde ND, Lin CW, Ogiela CA. Biaryl amide glucagon receptor antagonists. Bioorg Med Chem Lett 2004;14:2047-2050.
41. Hoare SR. Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors. Drug Discov Today 2005; 10:417-427.
42. Liaw CW, Grigoriadis DE, Lorang MT, De Souza EB, Maki RA. Localization of agonist- and antagonist-binding domains of human corticotropin-releasing factor receptors. Mol Endocrinol 1997; 11:2048-2053.
43. Kwakkenbos MJ, Kop EN, Stacey M, Matmati M, Gordon S, Lin HH, Hamann J. The EGF-TM7 family: a postgenomic view. Immunogenetics 2004;55:655-666.
44. Bjarnadottir TK, Fredriksson R, Hoglund PJ, Gloriam DE, Lagerstrom MC, Schioth HB. The human and mouse repertoire of the adhesion family of G-protein-coupled receptors. Genomics 2004;84: 23-33.
45. Pin JP, Galvez T, Prezeau L. Evolution, structure, and activation mechanism of family 3/C G-protein-coupled receptors. Pharmacol Ther 2003;98:325-354.
46. Goudet C, Gaven F, Kniazeff J, Vol C, Liu J, Cohen-Gonsaud M, Acher F, Prezeau L, Pin JP. Heptahelical domain of metabotropic glutamate receptor 5 behaves like rhodopsin-like receptors. Proc Natl Acad Sci USA 2004;101:378-383.
47. Malherbe P, Kratochwil N, Knoflach F, Zenner MT, Kew JN, Kratzeisen C, Maerki HP, Adam G, Mutel V. Mutational analysis and molecular modeling of the allosteric binding site of a novel, selective, noncompetitive antagonist of the metabotropic glutamate 1 receptor. J Biol Chem 2003;278:8340-8347.
48. Petrel C, Kessler A, Maslah F, Dauban P, Dodd RH, Rognan D, Ruat M. Modeling and mutagenesis of the binding site of Calhex 231, a novel negative allosteric modulator of the extracellular Ca(2+)-sensing receptor. J Biol Chem 2003;278:49487-49494.
49. Petrel C, Kessler A, Dauban P, Dodd RH, Rognan D, Ruat M. Positive and negative allosteric modulators of the Ca2+ -sensing receptor interact within overlapping but not identical binding sites in the transmembrane domain. J Biol Chem 2004;279:18990-18997.
50. Knoflach F, Mutel V, Jolidon S, Kew JN, Malherbe P, Vieira E, Wichmann J, Kemp JA. Positive allosteric modulators of metabotropic glutamate 1 receptor: characterization, mechanism of action, and binding site. Proc Natl Acad Sci USA 2001;98:13402-13407.
51. Kniazeff J, Galvez T, Labesse G, Pin J-P. No ligand binding in the GB2 subunit of the GABAB receptor is required for activation and allosteric interaction between the subunits. J Neurosci 2002;22: 7352-7361.
52. Binet V, Brajon C, Le Corre L, Acher F, Pin JP, Prezeau L. The heptahelical domain of GABA(B2) is activated directly by CGP7930, a positive allosteric modulator of the GABA(B) receptor. J Biol Chem 2004;279:29085-29091.
53. Urwyler S, Mosbacher J, Lingenhoehl K, Heid J, Hofstetter K, Froestl W, Bettler B, et al. Positive allosteric modulation of native and recombinant gamma-aminobutyric acid(B) receptors by 2,6-Di-tert-butyl-4-(3-hydroxy-2,2- dimethyl-propyl)-phenol (CGP7930) and its aldehyde analog CGP13501. Mol Pharmacol 2001;60:963-971.
54. Urwyler S, Pozza MF, Lingenhoehl K, Mosbacher J, Lampert C, Froestl W, Koller M, et al. N,N′-Dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4, 6-diamine (GS39783) and structurally related compounds: novel allosteric enhancers of gamma-aminobutyric acidB receptor function. J Pharmacol Exp Ther 2003;307:322-330.
55. Toh H, Ichikawa A, Narumiya S. Molecular evolution of receptors for eicosanoids. FEBS Lett 1995;361:17-21.
56. Regan JW, Bailey TJ, Pepperl DJ, Pierce KL, Bogardus AM, Donello JE, Fairbairn CE, et al. Cloning of a novel human prostaglandin receptor with characteristics of the pharmacologically defined EP2 subtype. Mol Pharmacol 1994;46:213-220.
57. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999;79:1193-1226.
58. Stitham J, Stojanovic A, Merenick BL, O'Hara KA, Hwa J. The unique ligand-binding pocket for the human prostacyclin receptor. Site-directed mutagenesis and molecular modeling. J Biol Chem 2003;278:4250-4257.
59. Kobayashi T, Ushikubi F, Narumiya S. Amino acid residues conferring ligand binding properties of prostaglandin I and prostaglandin D receptors. Identification by site-directed mutagenesis. J Biol Chem 2000;275:24294-24303.
60. Kobayashi T, Kiriyama M, Hirata T, Hirata M, Ushikubi F, Narumiya S. Identification of domains conferring ligand binding specificity to the prostanoid receptor. Studies on chimeric prostacyclin/prostaglandin D receptors. J Biol Chem 1997;272:15154-15160.
61. Elworthy TR, Kertesz DJ, Kim W, Roepel MG, Quattrocchio-Setti L, Smith DB, Tracy JL, et al. Lactams as EP(4) prostanoid receptor subtype selective agonists. Part 1: 2-pyrrolidinones-stereochemical and lower side-chain optimization. Bioorg Med Chem Lett 2004;14:1655-1659.
62. Mitsumori S, Tsuri T, Honma T, Hiramatsu Y, Okada T, Hashizume H, Inagaki M, et al. Synthesis and biological activity of various derivatives of a novel class of potent, selective, and orally active prostaglandin D2 receptor antagonists. 1. Bicyclo[2.2.1]heptane derivatives. J Med Chem 2003;46:2436-2445.
63. Vassart G, Pardo L, Costagliola S. A molecular dissection of the glycoprotein hormone receptors. Trends Biochem Sci 2004;29:119-126.
64. Lembo PM, Grazzini E, Groblewski T, O'Donnell D, Roy MO, Zhang J, Hoffert C, et al. Proenkephalin A gene products activate a new family of sensory neuron-specific GPCRs. Nat Neurosci 2002;5:201-209.
65. Dong X, Han S, Zylka MJ, Simon MI, Anderson DJ. A diverse family of GPCRs expressed in specific subsets of nociceptive sensory neurons. Cell 2001;106:619-632.
66. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, Heringer-Walther S, et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 2003;100:8258-8263.
67. Shinohara T, Harada M, Ogi K, Maruyama M, Fujii R, Tanaka H, Fukusumi S, et al. Identification of a G Protein-coupled Receptor Specifically Responsive to (beta)-Alanine. J Biol Chem 2004;279: 23559-23564.
68. Bender E, Buist A, Jurzak M, Langlois X, Baggerman G, Verhasselt P, Ercken M, et al. Characterization of an orphan G protein-coupled receptor localized in the dorsal root ganglia reveals adenine as a signaling molecule. Proc Natl Acad Sci USA 2002;99: 8573-8578
69. Han SK, Dong X, Hwang JI, Zylka MJ, Anderson DJ, Simon MI. Orphan G protein-coupled receptors MrgA1 and MrgC11 are distinctively activated by RF-amide-related peptides through the Galpha q/11 pathway. Proc Natl Acad Sci USA 2002;99:14740-14745.
70. Robas N, Mead E, Fidock M. MrgX2 is a high potency cortistatin receptor expressed in dorsal root ganglion. J Biol Chem 2003;278: 44400-44404.
71. Matsumoto M, Saito T, Takasaki J, Kamohara M, Sugimoto T, Kobayashi M, Tadokoro M, Matsumoto S, Ohishi T, Furuichi K. An evolutionarily conserved G-protein coupled receptor family, SREB, expressed in the central nervous system. Biochem Biophys Res Commun 2000;272:576-582.
72. Shen D, Jiang M, Hao W, Tao L, Salazar M, Fong HK. A human opsin-related gene that encodes a retinaldehyde-binding protein. Biochemistry 1994;33:13117-13125.
73. Fredriksson R, Hoglund PJ, Gloriam DE, Lagerstrom MC, Schioth HB. Seven evolutionarily conserved human rhodopsin G protein-coupled receptors lacking close relatives. FEBS Lett 2003;554:381-388.
74. Uhlenbrock K, Gassenhuber H, Kostenis E. Sphingosine 1-phosphate is a ligand of the human gpr3, gpr6 and gpr12 family of constitutively active G protein-coupled receptors. Cell Signal 2002;14:941-953.
75. Goto S, Okuno Y, Hattori M, Nishioka T, Kanehisa M. LIGAND: database of chemical compounds and reactions in biological pathways. Nucleic Acids Res 2002;30:402-404.
76. Wang DA, Lorincz Z, Bautista DL, Liliom K, Tigyi G, Parrill AL. A single amino acid determines lysophospholipid specificity of the S1P1 (EDG1) and LPA1 (EDG2) phospholipid growth factor receptors. J Biol Chem 2001;276:49213-49220.
77. Tigyi G. Selective ligands for lysophosphatidic acid receptor subtypes: gaining control over the endothelial differentiation gene family. Mol Pharmacol 2001;60:1161-1164.
78. Chin CN, Murphy JW, Huffman JW, Kendall DA. The third transmembrane helix of the cannabinoid receptor plays a role in the selectivity of aminoalkylindoles for CB2, peripheral cannabinoid receptor. J Pharmacol Exp Ther 1999;291:837-844.
79. Gouldson P, Calandra B, Legoux P, Kerneis A, Rinaldi-Carmona M, Barth F, Le Fur G, Ferrara P, Shire D. Mutational analysis and molecular modelling of the antagonist SR 144528 binding site on the human cannabinoid CB(2) receptor. Eur J Pharmacol 2000;401: 17-25.
80. Blaker M, Ren Y, Seshadri L, McBride EW, Beinborn M, Kopin AS. CCK-B/Gastrin receptor transmembrane domain mutations selectively alter synthetic agonist efficacy without affecting the activity of endogenous peptides. Mol Pharmacol 2000;58:399-406.
81. Escrieut C, Gigoux V, Archer E, Verrier S, Maigret B, Behrendt R, Moroder L, Bignon E, Silvente-Poirot S, Pradayrol L, Fourmy D. The biologically crucial C terminus of cholecystokinin and the non-peptide agonist SR-146,131 share a common binding Site in the Human CCK1 Receptor. Evidence for a crucial role of Met121 in the activation process. J Biol Chem 2002;277:7546-7555.
82. Berthold M, Bartfai T. Modes of peptide binding in G protein-coupled receptors. Neurochem Res 1997;22:1023-1031.
83. Berthold M, Kahl U, Jureus A, Kask K, Nordvall G, Langel U, Bartfai T. Mutagenesis and ligand modification studies on galanin binding to its GTP-binding-protein-coupled receptor GalR1. Eur J Biochem 1997;249:601-606.
84. Sautel M, Martinez R, Munoz M, Peitsch MC, Beck-Sickinger AG, Walker P. Role of a hydrophobic pocket of the human Y1 neuropeptide Y receptor in ligand binding. Mol Cell Endocrinol 1995;112: 215-222.
85. Breu V, Hashido K, Broger C, Miyamoto C, Furuichi Y, Hayes A, Kalina B, et al. Separable binding sites for the natural agonist endothelin-1 and the non-peptide antagonist bosentan on human endothelin-A receptors. Eur J Biochem 1995;231:266-270.
86. Giolitti A, Cucchi P, Renzetti AR, Rotondaro L, Zappitelli S, Maggi CA. Molecular determinants of peptide and nonpeptide NK-2 receptor antagonists binding sites of the human tachykinin NK-2 receptor by site-directed mutagenesis. Neuropharmacology 2000; 39:1422-1429.
87. Gouldson P, Legoux P, Carillon C, Delpech B, Le Fur G, Ferrara P, Shire D. Contrasting roles of leu(356) in the human CCK(1) receptor for antagonist SR 27897 and agonist SR 146131 binding. Eur J Pharmacol 1999;383:339-346.
88. Greenfeder S, Cheewatrakoolpong B, Billah M, Egan RW, Keene E, Murgolo NJ, Anthes JC. The neurokinin-1 and neurokinin-2 receptor binding sites of MDL103.392 differ. Bioorg Med Chem 1999;7:2867-2876.
89. Donohue PJ, Sainz E, Akeson M, Kroog GS, Mantey SA, Battey JF, Jensen RT, Northup JK. An aspartate residue at the extracellular boundary of TMII and an arginine residue in TMVII of the gastrin-releasing peptide receptor interact to facilitate heterotrimeric G protein coupling. Biochemistry 1999;38:9366-9372.
90. Akeson M, Sainz E, Mantey SA, Jensen RT, Battey JF. Identification of four amino acids in the gastrin-releasing peptide receptor that are required for high affinity agonist binding. J Biol Chem 1997;272:17405-17409.
91. Tokita K, Katsuno T, Hocart SJ, Coy DH, Llinares M, Martinez J, Jensen RT. Molecular basis for selectivity of high affinity peptide antagonists for the gastrin-releasing peptide receptor. J Biol Chem 2001;276:36652-36663.
92. Lin Y, Jian X, Lin Z, Kroog GS, Mantey S, Jensen RT, Battey J, Northup J. Two amino acids in the sixth transmembrane segment of the mouse gastrin-releasing peptide receptor are important for receptor activation. J Pharmacol Exp Ther 2000;294:1053-1062.
93. Tokita K, Hocart SJ, Katsuno T, Mantey SA, Coy DH, Jensen RT. Tyrosine 220 in the 5th transmembrane domain of the neuromedin B receptor is critical for the high selectivity of the peptoid antagonist PD168368. J Biol Chem 2001;276:495-504.
94. Wu C, Chan MF, Stavros F, Raju B, Okun I, Castillo RS. Structure-activity relationships of N2-aryl-3-(isoxazolylsulfamoyl)-2-thiophenecarboxamides as selective endothelin receptor-A antagonists. J Med Chem 1997;40:1682-1689.
95. Funk OF, Kettmann V, Drimal J, Langer T. Chemical function based pharmacophore generation of endothelin-A selective receptor antagonists. J Med Chem 2004;47:2750-2760.
96. Lee JA, Brinkmann JA, Longton ED, Peishoff CE, et al. Lysine 182 of endothelin B receptor modulates agonist selectivity and antagonist affinity: evidence for the overlap of peptide and non-peptide ligand binding sites. Biochemistry 1994;33:14543-14549.
97. Webb ML, Patel PS, Rose PM, Liu EC, Stein PD, Barrish J, Lach DA, et al. Mutational analysis of the endothelin type A receptor (ETA): interactions and model of selective ETA antagonist BMS-182874 with putative ETA receptor binding cavity. Biochemistry 1996;35:2548-2556.
98. Huang RR, Yu H, Strader CD, Fong TM. Interaction of substance P with the second and seventh transmembrane domains of the neurokinin-1 receptor. Biochemistry 1994;33:3007-3013.
99. Bhogal N, Donnelly D, Findlay JB. The ligand binding site of the neurokinin 2 receptor. Site-directed mutagenesis and identification of neurokinin A binding residues in the human neurokinin 2 receptor. J Biol Chem 1994;269:27269-27274.
100. Labrou NE, Bhogal N, Hurrell CR, Findlay JB. Interaction of Met297 in the seventh transmembrane segment of the tachykinin NK2 receptor with neurokinin A. J Biol Chem 2001;276: 37944-37949.
101. Renzetti AR, Catalioto RM, Criscuoli M, Cucchi P, Ferrer C, Giolitti A, Guelfi M, et al. Relevance of aromatic residues in transmembrane segments V to VII for binding of peptide and nonpeptide antagonists to the human tachykinin NK(2) receptor. J Pharmacol Exp Ther 1999;290:487-495.
102. Sautel M, Rudolf K, Wittneben H, Herzog H, Martinez R, Munoz M, Eberlein W, et al. Neuropeptide Y and the nonpeptide antagonist BIBP 3226 share an overlapping binding site at the human Y1 receptor. Mol Pharmacol 1996;50:285-292.
103. Kannoa T, Kanatani A, Keen SL, Arai-Otsuki S, Haga Y, Iwama T, Ishihara A, et al. Different binding sites for the neuropeptide Y Y1 antagonists 1229U91 and J-104870 on human Y1 receptors. Peptides 2001;22:405-413.
104. Conway S, Canning SJ, Barrett P, Guardiola-Lemaitre B, Delagrange P, Morgan PJ. The roles of valine 208 and histidine 211 in ligand binding and receptor function of the ovine Mel1a beta melatonin receptor. Biochem Biophys Res Commun 1997;239: 418-423.
105. Conway S, Drew JE, Mowat ES, Barrett P, Delagrange P, Morgan PJ. Chimeric melatonin mt1 and melatonin-related receptors. Identification of domains and residues participating in ligand binding and receptor activation of the melatonin mt1 receptor. J Biol Chem 2000;275:20602-20609.
106. Kokkola T, Foord SM, Watson MA, Vakkuri O, Laitinen JT. Important amino acids for the function of the human MT1 melatonin receptor. Biochem Pharmacol 2003;65:1463-1471.
107. Kokkola T, Watson MA, White J, Dowell S, Foord SM, Laitinen JT. Mutagenesis of human Mel1a melatonin receptor expressed in yeast reveals domains important for receptor function. Biochem Biophys Res Commun 1998;249:531-536.
108. Gubitz AK, Reppert SM. Chimeric and point-mutated receptors reveal that a single glycine residue in transmembrane domain 6 is critical for high affinity melatonin binding. Endocrinology 2000;141:1236-1244.
109. Gerdin MJ, Mseeh F, Dubocovich ML. Mutagenesis studies of the human MT2 melatonin receptor. Biochem Pharmacol 2003;66: 315-320.
110. Laitinen T, Polvi A, Rydman P, Vendelin J, Pulkkinen V, Salmikangas P, Makela S, et al. Characterization of a Common Susceptibility Locus for Asthma-Related Traits. Science 2004;304: 300-304.
111. Hibert M, Hoflack J, Trumpp-Kallmeyer S, Mouillac B, Chini B, Mahe E, Cotte N, et al. Functional architecture of vasopressin/oxytocin receptors. J Recept Signal Transduct Res 1999;19:589-596.
112. Phalipou S, Seyer R, Cotte N, Breton C, Barberis C, Hibert M, Mouillac B. Docking of linear peptide antagonists into the human V(1a) vasopressin receptor. Identification of binding domains by photoaffinity labeling. J Biol Chem 1999;274:23316-23327.
113. Tahtaoui C, Balestre MN, Klotz P, Rognan D, Barberis C, Mouillac B, Hibert M. Identification of the binding sites of the SR49059 nonpeptide antagonist into the V1a vasopressin receptor using sulfydryl-reactive ligands and cysteine mutants as chemical sensors. J Biol Chem 2003;278:40010-40019.
114. Derick S, Pena A, Durroux T, Wagnon J, Serradeil-Le Gal C, Hibert M, Rognan D, et al. Key amino acids located within the transmembrane domains 5 and 7 account for the pharmacological specificity of the human V1b vasopressin receptor. Mol Endocrinol 2004;18:2777-2789.
115. Murugesan N, Tellew JE, Gu Z, Kunst BL, Fadnis L, Cornelius LA, Baska RA, et al. Discovery of N-isoxazolyl biphenylsulfonamides as potent dual angiotensin II and endothelin A receptor antagonists. J Med Chem 2002;45:3829-3835.
116. Kakefuda A, Suzuki T, Tobe T, Tsukada J, Tahara A, Sakamoto S, Tsukamoto S. Synthesis and pharmacological evaluation of 5-(4-biphenyl)-3-methyl-4-phenyl- 1,2,4-triazole derivatives as a novel class of selective antagonists for the human vasopressin V(1A) receptor. J Med Chem 2002;45:2589-2598.
117. Pitt G, Batt A, Haigh R, Penson A, Robson P, Rooker D, Tartar A, et. al. Non-peptide oxytocin agonists. Bioorg Med Chem Lett 2004;14:4585-4589.
118. Flanagan CA, Millar RP, Illing N. Advances in understanding gonadotrophin-releasing hormone receptor structure and ligand interactions. Rev Reprod 1997;2:113-120.
119. Hoffmann SH, ter Laak T, Kuhne R, Reilander H, Beckers T. Residues within transmembrane helices 2 and 5 of the human gonadotropin-releasing hormone receptor contribute to agonist and antagonist binding. Mol Endocrinol 2000;14:1099-1115.
120. Hovelmann S, Hoffmann SH, Kuhne R, ter Laak T, Reilander H, Beckers T. Impact of aromatic residues within transmembrane helix 6 of the human gonadotropin-releasing hormone receptor upon agonist and antagonist binding. Biochemistry 2002;41: 1129-1136.
121. Jiang J, DeVita RJ, Goulet MT, Wyvratt MJ, Lo JL, Ren N, Yudkovitz JB, et al. Syntheses and structure-activity relationship studies of piperidine-substituted quinolones as nonpeptide gonadotropin releasing hormone antagonists. Bioorg Med Chem Lett 2004;14:1795-1798.
122. Gao ZG, Chen A, Barak D, Kim SK, Muller CE, Jacobson KA. Identification by site-directed mutagenesis of residues involved in ligand recognition and activation of the human A3 adenosine receptor. J Biol Chem 2002;277:19056-19063.
123. Barbhaiya H, McClain R, Ijzerman A, Rivkees SA. Site-directed mutagenesis of the human A1 adenosine receptor: influences of acidic and hydroxy residues in the first four transmembrane domains on ligand binding. Mol Pharmacol 1996;50:1635-1642.
124. Rivkees SA, Barbhaiya H, AP IJ. Identification of the adenine binding site of the human A1 adenosine receptor. J Biol Chem 1999;274:3617-3621.
125. Cho W, Taylor LP, Mansour A, Akil H. Hydrophobic residues of the D2 dopamine receptor are important for binding and signal transduction. J Neurochem 1995;65:2105-2115.
126. Javitch JA, Ballesteros JA, Weinstein H, Chen J. A cluster of aromatic residues in the sixth membrane-spanning segment of the dopamine D2 receptor is accessible in the binding-site crevice. Biochemistry 1998;37:998-1006.
127. Roth BL, Willins DL, Kristiansen K, Kroeze WK. 5-Hydroxytryptamine2- family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamine2C): where structure meets function. Pharmacol Ther 1998;79:231-257.
128. Joubert L, Claeysen S, Sebben M, Bessis AS, Clark RD, Martin RS, Bockaert J, et al. A 5-HT4 receptor transmembrane network implicated in the activity of inverse agonists but not agonists. J Biol Chem 2002;277:25502-25511.
129. Shi L, Liapakis G, Xu R, Guarnieri F, Ballesteros JA, Javitch JA. Beta2 adrenergic receptor activation. Modulation of the proline kink in transmembrane 6 by a rotamer toggle switch. J Biol Chem 2002;277:40989-40996.
130. Ballesteros JA, Jensen AD, Liapakis G, Rasmussen SG, Shi L, Gether U, Javitch JA. Activation of the beta 2-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6. J Biol Chem 2001;276: 29171-29177.
131. Kobilka B. Agonist binding: a multistep process. Mol Pharmacol 2004;65:1060-1062.
132. Wess J, Blin N, Mutschler E, Bluml K. Muscarinic acetylcholine receptors: structural basis of ligand binding and G protein coupling. Life Sci 1995;56:915-922.
133. Wieland K, Zuurmond HM, Krasel C, Ijzerman AP, Lohse MJ. Involvement of Asn-293 in stereospecific agonist recognition and in activation of the beta 2-adrenergic receptor. Proc Natl Acad Sci USA 1996;93:9276-9281.
134. Shin N, Coates E, Murgolo NJ, Morse KL, Bayne M, Strader CD, Monsma Jr FJ. Molecular modeling and site-specific mutagenesis of the histamine-binding site of the histamine H4 receptor. Mol Pharmacol 2002;62:38-47.
135. Gantz I, DelValle J, Wang LD, Tashiro T, Munzert G, Guo YJ, Konda Y, et al. Molecular basis for the interaction of histamine with the histamine H2 receptor. J Biol Chem 1992;267:20840-20843.
136. Wieland K, Laak AM, Smit MJ, Kuhne R, Timmerman H, Leurs R. Mutational analysis of the antagonist-binding site of the histamine H(1) receptor. J Biol Chem 1999;274:29994-30000.
137. Bissantz C, Bernard P, Hibert M, Rognan D. Protein-based virtual screening of chemical databases. II. Are homology models of G-Protein Coupled Receptors suitable targets? Proteins 2003; 50:5-25.
138. Javitch JA, Ballesteros JA, Chen J, Chiappa V, Simpson MM. Electrostatic and aromatic microdomains within the binding-site crevice of the D2 receptor: contributions of the second membrane-spanning segment. Biochemistry 1999;38:7961-7968.
139. Simpson MM, Ballesteros JA, Chiappa V, Chen J, Suehiro M, Hartman DS, Godel T, et al. Dopamine D4/D2 receptor selectivity is determined by A divergent aromatic microdomain contained within the second, third, and seventh membrane-spanning segments. Mol Pharmacol 1999;56:1116-1126.
140. Nijenhuis WAJ, Oosterom J, Adan RAH. AgRP(83-132) acts as an inverse agonist on the human-melanocortin-4 receptor. Mol Endocrinol 2001;15:164-171.
141. Yang YK, Fong TM, Dickinson CJ, Mao C, Li JY, Tota MR, Mosley R, et al. Molecular determinants of ligand binding to the human melanocortin-4 receptor. Biochemistry 2000;39:14900-14911.
142. Nickolls SA, Cismowski MI, Wang X, Wolff M, Conlon PJ, Maki RA. Molecular determinants of melanocortin 4 receptor ligand binding and MC4/MC3 receptor selectivity. J Pharmacol Exp Ther 2003;304:1217-1227.
143. Schioth HB, Muceniece R, Szardenings M, Prusis P, Lindeberg G, Sharma SD, Hruby VJ, et al. Characterisation of D117A and H260A mutations in the melanocortin 1 receptor. Mol Cell Endocrinol 1997;126:213-219.
144. Yang Y, Dickinson C, Haskell-Luevano C, Gantz I. Molecular basis for the interaction of [Nle4,D-Phe7]melanocyte stimulating hormone with the human melanocortin-1 receptor. J Biol Chem 1997;272:23000-23010.
145. Chen C, Yu J, Fleck BA, Hoare SRJ, Saunders J, Foster AC. Phenylguanidines as selective onpeptide melanocortin-5 receptor antagonists. J Med Chem 2004;47:4083-4088.
146. McKee KK, Tan CP, Palyha OC, Liu J, Feighner SD, Hreniuk DL, Smith RG, et al. Cloning and characterization of two human G protein-coupled receptor genes (GPR38 and GPR39) related to the growth hormone secretagogue and neurotensin receptors. Genomics 1997;46:426-434.
147. Feighner SD, Howard AD, Prendergast K, Palyha OC, Hreniuk DL, Nargund R, Underwood D, et al. Structural requirements for the activation of the human growth hormone secretagogue receptor by peptide and nonpeptide secretagogues. Mol Endocrinol 1998;12:137-145.
148. Labbe-Jullie C, Barroso S, Nicolas-Eteve D, Reversat JL, Botto JM, Mazella J, Bernassau JM, et al. Mutagenesis and modeling of the neurotensin receptor NTR1. Identification of residues that are critical for binding SR 48692, a nonpeptide neurotensin antagonist. J Biol Chem 1998;273:16351-16357.
149. Colson AO, Perlman JH, Jinsi-Parimoo A, Nussenzveig DR, Osman R, Gershengorn MC. A hydrophobic cluster between transmembrane helices 5 and 6 constrains the thyrotropin-releasing hormone receptor in an inactive conformation. Mol Pharmacol 1998;54:968-978.
150. Perlman JH, Laakkonen L, Osman R, Gershengorn MC. Distinct roles for arginines in transmembrane helices 6 and 7 of the thyrotropin-releasing hormone receptor. Mol Pharmacol 1995;47: 480-484.
151. Perlman JH, Laakkonen LJ, Guarnieri F, Osman R, Gershengorn MC. A refined model of the thyrotropin-releasing hormone (TRH) receptor binding pocket. Experimental analysis and energy minimization of the complex between TRH and TRH receptor. Biochemistry 1996;35:7643-7650.
152. Perlman JH, Thaw CN, Laakkonen L, Bowers CY, Osman R, Gershengorn MC. Hydrogen bonding interaction of thyrotropin-releasing hormone (TRH) with transmembrane tyrosine 106 of the TRH receptor. J Biol Chem 1994;269:1610-1613.
153. Clark DE, Higgs C, Wren SP, Dyke HJ, Wong M, Norman D, Lockey PM, Roach AG. A virtual screening approach to finding novel and potent anatgonists at the melanin-concentrating hormone 1 receptor. J Med Chem 2004;47:3962-3971.
154. Macdonald D, Murgolo N, Zhang R, Durkin JP, Yao X, Strader CD, Graziano MP. Molecular characterization of the melanin-concentrating hormone/receptor complex: identification of critical residues involved in binding and activation. Mol Pharmacol 2000;58:217-225.
155. Receveur JM, Bjurling E, Ulven T, Little PB, Norregaard PK, Hogberg T. 4-Acylamino-and 4-ureidobenzamides as melanin-concentrating hormone (MCH) receptor 1 antagonists. Bioorg Med Chem Lett 2004;14:5075-5080.
156. Tunaru S, Kero J, Schaub A, Wufka C, Blaukat A, Pfeffer K, Offermanns S. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med 2003;9:352-355.
157. Jones CE, Holden S, Tenaillon L, Bhatia U, Seuwen K, Tranter P, Turner J, et al. Expression and characterization of a 5-oxo-6E,8Z,11Z,14Z- eicosatetraenoic acid receptor highly expressed on human eosinophils and neutrophils. Mol Pharmacol 2003;63: 471-477.
158. Dragic T, Trkola A, Thompson DA, Cormier EG, Kajumo FA, Maxwell E, Lin SW, et al. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc Natl Acad Sci USA 2000;97:5639-5644.
159. Mirzadegan T, Diehl F, Ebi B, Bhakta S, Polsky I, McCarley D, Mulkins M, et al. Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists: binding to a common chemokine receptor motif within the helical bundle. J Biol Chem 2000;275:25562-25571.
160. Hatse S, Princen K, Gerlach LO, Bridger G, Henson G, De Clercq E, Schwartz TW, et al. Mutation of Asp(171) and Asp(262) of the chemokine receptor CXCR4 impairs its coreceptor function for human immunodeficiency virus-1 entry and abrogates the antagonistic activity of AMD3100. Mol Pharmacol 2001;60:164-173.
161. Castonguay LA, Weng Y, Adolfsen W, Di Salvo J, Kilburn R, Caldwell CG, Daugherty BL, et al. Binding of 2-aryl-4-(piperidin-1-yl)butanamines and 1,3,4-trisubstituted pyrrolidines to human CCR5: a molecular modeling-guided mutagenesis study of the binding pocket. Biochemistry 2003;42:1544-1550.
162. Patel YC, Greenwood MT, Panetta R, Demchyshyn L, Niznik H, Srikant CB. The somatostatin receptor family. Life Sci 1995;57: 1249-1265.
163. Simon A, Czajlik A, Perczel A, Keri G, Nyikos L, Emri Z, Kardos J. Binding crevice for TT-232 in a homology model of type 1 somatostatin receptor. Biochem Biophys Res Commun 2004;316: 1059-1064.
164. Kaupmann K, Bruns C, Raulf F, Weber HP, Mattes H, Lubbert H. Two amino acids, located in transmembrane domains VI and VII, determine the selectivity of the peptide agonist SMS 201-995 for the SSTR2 somatostatin receptor. EMBO J 1995;14:727-735.
165. Rohrer SP, Birzin ET, Mosley RT, Berk SC, Hutchins SM, Shen DM, Xiong Y, et al. Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science 1998;282:737-740.
166. Poitout L, Roubert P, Contour-Galcera MO, Moinet C, Lannoy J, Pommier J, Plas P, et al. Identification of potent non-peptide somatostatin antagonists with sst(3) selectivity. J Med Chem 2001;44:2990-3000.
167. Befort K, Tabbara L, Bausch S, Chavkin C, Evans C, Kieffer B. The conserved aspartate residue in the third putative transmembrane domain of the delta-opioid receptor is not the anionic counterpart for cationic opiate binding but is a constituent of the receptor binding site. Mol Pharmacol 1996;49:216-223.
168. Befort K, Tabbara L, Kling D, Maigret B, Kieffer BL. Role of aromatic transmembrane residues of the delta-opioid receptor in ligand recognition. J Biol Chem 1996;271:10161-10168.
169. Meng F, Ueda Y, Hoversten MT, Taylor LP, Reinscheid RK, Monsma FJ, Watson SJ, et al. Creating a functional opioid alkaloid binding site in the orphanin FQ receptor through site-directed mutagenesis. Mol Pharmacol 1998;53:772-777.
170. Chen Z, Zhang X, Gonnella NC, Pellas TC, Boyar WC, Ni F. Residues 21-30 within the extracellular N-terminal region of the C5a receptor represent a binding domain for the C5a anaphylatoxin. J Biol Chem 1998;273:10411-10419.
171. DeMartino JA, Konteatis ZD, Siciliano SJ, Van Riper G, Underwood DJ, Fischer PA, Springer MS. Arginine 206 of the C5a receptor is critical for ligand recognition and receptor activation by C-terminal hexapeptide analogs. J Biol Chem 1995;270:15966-15969.
172. Gerber BO, Meng EC, Dotsch V, Baranski TJ, Bourne HR. An activation switch in the ligand binding pocket of the C5a receptor. J Biol Chem 2001;276:3394-3400.
173. Cain SA, Coughlan T, Monk PN. Mapping the ligand-binding site on the C5a receptor: arginine74 of C5a contacts aspartate282 of the C5a receptor. Biochemistry 2001;40:14047-14052.
174. de Laszlo SE, Allen EE, Li B, Ondeyka D, Rivero R, Malkowitz L, Molineaux C, et al. A nonpeptidic agonist ligand of the human C5a receptor: synthesis, binding affinity optimization and functional characterization. Bioorg Med Chem Lett 1997;7:213-218.
175. Astles PC, Brown TJ, Cox P, Halley F, Lockey PM, McCarthy C, McLay IM, et al. New non peptidic C5a receptor antagonists. Bioorg Med Chem Lett 1997;7:907-912.
176. Mills JS, Miettinen HM, Cummings D, Jesaitis AJ. Characterization of the binding site on the formyl peptide receptor using three receptor mutants and analogs of Met-Leu-Phe and Met-Met-Trp-Leu-Leu. J Biol Chem 2000;275:39012- 39017.
177. Chen X, Yang D, Shen W, Dong HF, Wang JM, Opppenheim JJ, Howard OMZ. Characterization of chenodeoxycholic acid as an endogenous antagonist of the G-coupled formyl peptide receptors. Inflamm Res 2000;49:744-755.
178. Liang TS, Gao J-L, Fatemi O, Lavigne M, Leto TL, Murphy PM. The endogenous opioid spinorphin blocks fMet-Leu-Phe-induced neutrophil chemotaxis by acting as a specific antagonist at the N-formylpeptide receptor subtype FPR. J Immunol 2001;167: 6609-6614.
179. Dalpiaz A, Ferretti ME, Vertuani G, Traniello S, Scatturin A, Spisani S. C- and N-terminal residue effect on peptide derivatives' antagonism toward the formyl-peptide receptor. Eur J Pharmacol 2002;436:187-196.
180. Fierens FL, Vanderheyden PM, Gaborik Z, Minh TL, Backer JP, Hunyady L, Ijzerman A, et al. Lys(199) mutation of the human angiotensin type 1 receptor differentially affects the binding of surmountable and insurmountable non-peptide antagonists. J Renin Angiotensin Aldosterone Syst 2000;1:283-288.
181. Ji H, Leung M, Zhang Y, Catt KJ, Sandberg K. Differential structural requirements for specific binding of nonpeptide and peptide antagonists to the AT1 angiotensin receptor. Identification of amino acid residues that determine binding of the antihypertensive drug losartan. J Biol Chem 1994;269:16533-16536.
182. Marie J, Richard E, Pruneau D, Paquet JL, Siatka C, Larguier R, Ponce C, et al. Control of conformational equilibria in the human B2 bradykinin receptor. Modeling of nonpeptidic ligand action and comparison to the rhodopsin structure. J Biol Chem 2001;276: 41100-41111.
183. Bascands JL, Schanstra JP, Couture R, Girolami JP. Bradykinin receptors: towards new pathophysiological roles. Med Sci (Paris) 2003;19:1093-1100.
184. Fathy DB, Mathis SA, Leeb T, Leeb-Lundberg LM. A single position in the third transmembrane domains of the human B1 and B2 bradykinin receptors is adjacent to and discriminates between the C-terminal residues of subtype-selective ligands. J Biol Chem 1998;273:12210-12218.
185. He W, Miao FJ, Lin DC, Schwandner RT, Wang Z, Gao J, Chen JL, et al. Citric acid cycle intermediates as ligands for orphan G-protein-coupled receptors. Nature 2004;429:188-193.
186. Costanzi S, Mamedova L, Gao ZG, Jacobson KA. Architecture of P2Y nucleotide receptors: structural comparison based on sequence analysis, mutagenesis, and homology modeling. J Med Chem 2004;47:5393-5404.
187. Jiang Q, Guo D, Lee BX, Van Rhee AM, Kim YC, Nicholas RA, Schachter JB, et al. A mutational analysis of residues essential for ligand recognition at the human P2Y1 receptor. Mol Pharmacol 1997;52:499-507.
188. Moro S, Guo D, Camaioni E, Boyer JL, Harden TK, Jacobson KA. Human P2Y1 receptor: molecular modeling and site-directed mutagenesis as tools to identify agonist and antagonist recognition sites. J Med Chem 1998;41:1456-1466.
189. Noguchi K, Ishii S, Shimizu T. Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. J Biol Chem 2003;278:25600-25606.
190. Zhang HC, McComsey DF, White KB, Addo MF, Andrade-Gordon P, Derian CK, Oksenberg D, et al. Thrombin receptor (PAR-1) antagonists. Solid-phase synthesis of indole-based peptide mimetics by anchoring to a secondary amide. Bioorg Med Chem Lett 2001;11:2105-2109.
191. Schuffenhauer A, Zimmermann J, Stoop R, van der Vyver JJ, Lecchini S, Jacoby E. An ontology for pharmaceutical ligands and its application for in silico screening and library design. J Chem Inf Comput Sci 2002;42:947-955.
192. Balakin KV, Tkachenko SE, Lang SA, Okun I, Ivashchenko AA, Savchuk NP. Property-based design of GPCR-targeted library. J Chem Inf Comput Sci 2002;42:1332-1342.
193. von Korff M, Steger M. GPCR-tailored pharmacophore pattern recognition of small molecular ligands. J Chem Inf Comput Sci 2004;44:1137-1147.
194. Smith RG, Cheng K, Schoen WR, Pong SS, Hickey G, Jacks T, Butler B, et al. A nonpeptidyl growth hormone secretagogue. Science 1993;260:1640-1643.
195. Reiter LA, Koch K, Piscopio AD, Showell HJ, Alpert R, Biggers MS, Chambers RJ, et al. trans-3-Benzyl-4-hydroxy-7-chromanyl-benzoic acid derivatives as antagonists of the leukotriene B4 (LTB4) receptor. Bioorg Med Chem Lett 1998;8:1781-1786.
196. Guo T, Hobbs DW. Privileged structure-based combinatorial libraries targeting G protein-coupled receptors. Assay Drug Dev Technol 2003;1:579-592.
197. Bleicher KH, Bohm HJ, Muller K, Alanine AI. Hit and lead generation: beyond high-throughput screening. Nat Rev Drug Discov 2003;2:369-378.
198. Frimurer T, Ulven T, Elling CE, Gerlach LO, Kostenis E, Högberg T. A physicogenetic method to assign ligand-binding relationsships between 7TM receptors. Bioorg Med Chem Lett 2005;15:3707-3712.